58 results about "Human herpes virus" patented technology

The present invention relates to a group of novel viral RNA regulatory genes, here identified as “viral genomic address messenger genes” or “VGAM genes”, and as “genomic record” or “GR” genes. VGAM genes selectively inhibit translation of known host target genes, and are believed to represent a novel pervasive viral attack mechanism. GR genes encode an operon-like cluster of VGAM genes. VGAM and viral GR genes may therefore be useful in diagnosing, preventing and treating viral disease. Several nucleic acid molecules are provided respectively encoding several VGAM genes, as are vectors and probes, both comprising the nucleic acid molecules, and methods and systems for detecting VGAM genes, and for counteracting their activity.

The present invention provides methods, compositions, and kits related to nucleic acid detection assays for detecting human herpes virus. For example, the present invention provides detection assays for detecting human herpes virus subtypes HHV1- through HHV-8.

The invention discloses a reagent for rapidly detecting various subtypes of human herpes viruses. The reagent comprises forward and reverse primers specifically amplifying HSV-1 RL2, HSV-2 UL28, VZV ORF26, EBV EBNA1, HCMV IE, HHV-6A or HHV-6B U22, HHV-6A or HHV-6B IE, HHV-7 U95 and KSHV ORF72 and a corresponding internal reference standard. The invention also discloses a kit which contains the detection reagent and is used for rapidly detecting various subtypes of the human herpes viruses and also discloses a reagent which contains the detection reagent and is used for rapidly quantifying the various subtypes of the human herpes viruses as well as a detection quantification kit. The reagent disclosed by the invention can rapidly and effectively identify and diagnose the various subtypes on clinical samples in early stage of infection and with different sources, also can conveniently and accurately carry out virus copy number quantitative calculation and has high clinical diagnosis use value.

The invention provides a triple detection kit for human herpes viruses HSV-1, HSV-2 and HCMV. The triple detection kit is composed of a quantitative PCR (Polymerase Chain Reaction) reaction liquid, an HSV-1 standard substance, an HSV-2 standard substance, an HCMV standard substance, a negative reference substance, an HSV-1 positive reference substance, an HSV-2 positive reference substance, an HCMV positive reference substance, a specification and a box, wherein the quantitative PCR reaction liquid contains a PCR buffer solution, MgC12, dNTPs (deoxyriboNucleoside Tri-Phosphates), a heat-resisting DNA polymerase, an upstream amplification primer, a downstream amplification primer, an HSV-1 fluorescent probe, an HSV-2 fluorescent probe and an HCMV fluorescent probe. The kit is capable of realizing simultaneous typing detection on the common human herpes viruses HSV-1, HSV-2 and HCMV in a sample by virtue of the real-time quantitative PCR technique and the specific fluorescent probes of three colors; the kit is capable of quantifying positive viruses accurately in real time, so that the production cost and the detection cost can be saved and the detection efficiency can be improved; besides, the kit is capable of meeting diagnosis requirements and helpful for formulating a targeting treatment scheme timely.

Compositions and methods are provided for the treatment and diagnosis of herpesvirus infections. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with RNA or DNA deriving from a gene corresponding to one of the open reading frames UL5, UL8, UL9, UL13, UL29, UL30, UL39, UL40, UL42 AND UL52 of herpes simplex virus type 1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a translation initiation site; it is also preferred that they comprise the sequence CAT. Methods of treating animals suspected of being infected with herpesvirus comprising contacting the animal with an oligonucleotide specifically hybridizable with RNA or DNA deriving from one of the foregoing genes of the herpesvirus are disclosed. Methods for treatment of infections caused by herpes simplex virus type 1, herpes simplex virus type 2, cytomegalovirus, human herpes virus 6, Epstein Barr virus or varicella zoster virus are disclosed.

The invention discloses a detection method of brucella. The detection method comprises the following steps: acquiring brucella DNA from a serum sample by adopting a centrifugal column method, thus obtaining a to-be-detected sample; carrying out PCR amplification reaction; detecting a reaction result by adopting a fluorescence quantitative PCR instrument, wherein during fluorescence signal collection, fluorescein corresponding to fluorophore at the BKV-FP 5' end of a Taqman fluorescence probe is set, and the fluorescence signals are collected at 60 DEG C; and analyzing the result. The invention further provides a kit for detecting the brucella. The detection method and the kit are high in sensitivity, and the minimal detection can achieve 1000 copies / mL. Meanwhile, the detection method is good in specificity, and the cross reaction with other bacteria, such as escherichia coli, salmonella enteritidis, hepatitis B virus, human herpes virus 4, and human cytomegalovirus can be avoided.

The invention provides a screening and modification method, a marker and an application of polypeptide drugs which are used in the treatment of CXCR4 receptor-mediated breast cancer. A human chemokine SDF-1 Alpha and the homology region of a human herpes virus 8 MIP-II are compared, thereby obtaining a binding site of vMIP-II and CXCR4 receptor and further obtaining a CXCR4 specific binding active peptide. With the role of specific binding CXCR4 and the blocking of the physiological binding of the SDF-1 Alpha and the CXCR4, the CXCR4 specific binding active peptide is a high-efficient and specific chemokine receptor antagonist. The chemotactic activity of wide type SDF-1 Alpha to breast cancer cells and the growth of the breast cancer cells can be inhibited, and the growth and the metastasis of the CXCR4-positive tumor cells are simultaneously inhibited, thereby having the dual-target effect. The invention further provides a marked polypeptide to be targetedly positioned in sentinel lymph node and metastatic site, thereby being used in the detection and the targeted radiotherapy of the metastatic status of the sentinel lymph node before and in the operation of the breast cancer.

The invention discloses an application of a benzo Alpha-pyrone compound as a Gamma-type human herpes virus-resistant medicine. According to the invention, the compound resistant to Gamma-type human herpes virus infection is higher in activity as compared with a novobiocin which is a marketed medicine, and is less in toxicity based on a cytoxicity test. The compound can be used for curing or preventing related diseases caused by KSHV infection.

The invention provides a recombinant protein vaccine. The recombinant protein vaccine contains an epitope of EB virus antigen 1 (EBNA1) and an epitope of human herpes virus glycoprotein; fusion proteins can effectively activate a specific cell toxic T lymphocyte (CTL) reaction, directly restrain the expression EBNA1, and give play to treatment effects on EB virus-associated tumors; an immunosuppression path can be directly blocked through herpes virus glycoprotein, and the activity of regulatory T cells is improved. In this way, by means of the recombinant protein vaccine, EB virus infections and diseases related to the EB virus infections and tumors related to the EB virus infections can be prevented or treated in a multi-way manner more comprehensively. The invention further provides a recombinant expression vector containing genes for coding the recombinant protein vaccine and application of the recombinant protein vaccine.

The invention provides an expression system for a nonintegrated, long-time and erasable expression vector. The expression vector of the expression system adopts human herpes virus replication origin (Orip), an EBNA-1 expression box is introduced, and both ends of the Orip, both end of EBN-1 or both ends of Orip-EBNA-1 are provided with recombinase recognition sequences. The expression vector is not integrated in a cell genome, can stably express for a long time, can controllably erase vector plasmid by instantaneously inducing (or expressing) recombinase from a hose cell, can be applied to most kinds of cells by using a strong initiator and can distinguish a cell with the vector plasmid from a cell without the vector plasmid by using a real-time marker. The expression system can widely applied to mammal cell expression and biomedicine engineering for realizing cell reprogramming by expressing a foreign gene.

The invention discloses application of a 2-furan acrylaldehyde compound to preparation of a medicine for resisting human gamma-herpes virus. The 2-furan acrylaldehyde compound provided by the invention can be used for inhibiting lytic replication of the human gamma-herpes virus; compared with a marketing drug, namely acyclovir, the 2-furan acrylaldehyde compound has relatively small toxicity and the activity is equivalent. Therefore, the compound has a good application prospect in treatment of related diseases caused by KSHV (Kaposi's Sarcoma-associated Herpesvirus) and EBV (Ebola Virus) infection.

An isolated protein comprises respective amino acid sequences of each of a plurality of CTL epitopes from two or more different herpesvirus antigens and further comprises an intervening amino acid or amino acid sequence between at least two of said CTL epitopes comprising proteasome liberation amino acids or amino acid sequences and, optionally, Transporter Associated with Antigen Processing recognition motifs. The isolated protein is capable of rapidly expanding human cytotoxic T lymphocytes (CTL) in vitro and eliciting a CTL immune response in vivo upon administration to an animal as an exogenous protein. Typically, the isolated protein comprises no more than twenty (20) CTL epitopes derived from cytomegalovirus and / or Epstein-Barr virus antigens.

The invention provides a use of Tenovin-1 in preparing a drug. The drug is used for treating or preventing herpes virus infection. According to the embodiment of the invention, the Tenovin-1 can be effectively used for treating or preventing herpes virus infection. Detection on herpes viruses in different subtypes shows that, the Tenovin-1 has the activity of broad-spectrum anti-herpes viruses, ishigh in selection index, can be developed into a drug for treating herpes virus infection diseases and has a wide application prospect.

The invention discloses a primer, a probe and a kit for synchronously detecting human herpes virus types 6, 7 and 8. By selecting a new target gene, redesigning a primer and a kit, and optimizing a reaction system, the false positive rate of clinical synchronous detection on human herpes viruses is greatly reduced, the primer, the probe and the kit are good in sensitivity, good in specificity and short in detection time, and the technique can be applied to clinical application and popularization.

The invention provides a human herpes virus six-type real-time fluorescence quantitative PCR (polymerase chain reaction) kit, and relates to a PCR kit in the technical field of the biology. The kit comprises a pair of specific primers, a specific fluorescent probe, a positive control, a negative control, a 5*PCR Buffer and an Enzyme Mix, wherein the specific primers are designed to be: F: 5'-ACAAAGCGAAATTATCCAGAGCGT-3', and R: 5'-GCGCTAGGTTGAGGATGATCGC-3'; and the specific probe is designed to be: FP: 5'-FAM-ACACCAGACGTCACACCCGAAGGAATT-TAMARA3'. The kit is short in detection period, high in efficiency, high in viral specificity detection, high in accuracy, qualitative and quantitative in virus analysis, higher in the sensitivity compared with the common PCR and immunology detection method, simple in operation, easy to popularize, and good in the repeatability of the experimental result.

The invention belongs to the technical field of biomedicine, and relates to a human herpes virus hominis pyrolysis, reproduction and activation detection marker, in particular to the purpose of a signal transducer and activator of transcription 6 (Signal transducer and activator of transcription 6,STAT6) as the human herpes virus hominis pyrolysis, reproduction and activation detection marker. Target protein-STAT6 which is consistently regulated during human herpes virus pyrolysis and reproduction is obtained from the host angle, the experiment result shows that the STAT6 protein is significantly reduced in the infection course of Kaposi sarcoma herpesvirus (KSHV), and the STAT6 protein can be used as the marker for detecting pyrolysis, reproduction and activation of various herpes viruses, can be further used as a common target for diagnosing and treating herpes virus relevant tumor diseases, and can be further used for preparing products for preventing, detecting and treating human herpes virus hominis infection.

The present invention provides a method for treating patients with human herpes virus infection, comprising: raising the patient's core body temperature at least once and then returning to normal, the core body temperature is raised to a temperature and duration sufficient to reduce or eliminate the patient's human herpes virus load.

The invention relates to the field of detection of microorganisms and nucleic acid genomes, in particular to a primer combination and a probe for detecting nucleic acids of a clinically common human herpes virus (cytomegalovirus) by using an isothermal nucleic acid amplification technology. The primer combination and the probe provided by the invention are good in specificity and high in sensitivity.

The present invention provides methods of unambiguously identifying a human herpesvirus in a sample. The assays, which allow for the detection and typing of all ten human herpesviruses, involve multiplex PCR assays using consensus primers to amplify conserved regions of the herpesvirus DNA. A dot blot / chemiluminescence assay and real time PCR assay ideal for clinical setting were disclosed. A heteroduplex mobility assay suitable for uses in research laboratory was also presented.

The present invention provides: 1) Derivative solid form of 9-[2-(R)-[bis[pivaloyloxymethoxy]-phosphinylmethoxy]propyl]adenine (bis-POM PMPA, abbreviated as TD hereinafter), including crystalline form A and form B of TD, TD fumarate salts and cyclodextrin inclusion complex of TD; 2) Synthesis and purification methods of TD and Solidification method of TD oil, including converting TD oil to crystalline TD in Form A and Form B, solid TD salts and cyclodextrin inclusion complex of TD; 3) Stable pharmaceutical compositions containing TD derivatives and their preparation; 4) The use of the above TD derivatives in the antiviral treatments, especially in the treatment of HIV, HBV, CMV, HSV-1, HSV-2 and human Herpes virus infections.

The invention discloses a method for detecting pathogens infected by cerebrospinal fluid based on PCR (polymerase chain reaction) and nanopore sequencing. Experiments prove that the method provided by the invention is used for detecting the cerebrospinal fluid, and the method can be used for accurately judging which one or more of pathogens for infecting the central nervous system is or are selected from the group consisting of Enterovirus, Lymphotic virus, Neisseria meningiosis, Cytomegalovirus, Mycobacterium tubers, Nocardia Farcina, Herpes simplex virus 1, Human herpes virus 6, Listeria monocytogenes and Herpes simplex virus 2. The invention provides accurate and rapid etiological diagnosis for central nervous system infection, and has very high clinical application value.

The present invention provides methods for inhibition of human herpes virus replication in a subject comprising administering to the subject a therapeutically effective amount of a pharmaceutically acceptable composition comprising a cardiac glycoside analog, including for example, a digitoxin analog and pharmaceutically acceptable carrier. Other methods of the present invention include administering a digitoxin analog along with at least one other biologically active compound and pharmaceutically acceptable carrier. Methods for inhibition of the α3 subtype of the Na / K ATPase in a subject comprising administering to the subject a therapeutically effective amount of a pharmaceutically acceptable composition comprising a digitoxin analog are also provided.